CN106138129A - A kind of Chinese medicine compound thermosensitive hydrogel agent treating oral ulcer disease - Google Patents
A kind of Chinese medicine compound thermosensitive hydrogel agent treating oral ulcer disease Download PDFInfo
- Publication number
- CN106138129A CN106138129A CN201610716756.5A CN201610716756A CN106138129A CN 106138129 A CN106138129 A CN 106138129A CN 201610716756 A CN201610716756 A CN 201610716756A CN 106138129 A CN106138129 A CN 106138129A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine compound
- thermosensitive hydrogel
- oral ulcer
- ulcer disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 60
- 208000002399 aphthous stomatitis Diseases 0.000 title claims abstract description 43
- 208000007117 Oral Ulcer Diseases 0.000 title claims abstract description 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 37
- 239000000017 hydrogel Substances 0.000 title claims abstract description 34
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 31
- 150000001875 compounds Chemical class 0.000 title claims abstract description 29
- 239000012567 medical material Substances 0.000 claims abstract description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000000605 extraction Methods 0.000 claims abstract description 17
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 15
- 239000012676 herbal extract Substances 0.000 claims abstract description 14
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000002904 solvent Substances 0.000 claims abstract description 12
- 239000000758 substrate Substances 0.000 claims abstract description 11
- 235000014220 Rhus chinensis Nutrition 0.000 claims abstract description 6
- 240000003152 Rhus chinensis Species 0.000 claims abstract description 6
- 239000000499 gel Substances 0.000 claims description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 229920001983 poloxamer Polymers 0.000 claims description 14
- 239000008213 purified water Substances 0.000 claims description 13
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 11
- 229960000502 poloxamer Drugs 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 229920001993 poloxamer 188 Polymers 0.000 claims description 6
- 229940044519 poloxamer 188 Drugs 0.000 claims description 6
- -1 Acritamer 940 Chemical compound 0.000 claims description 4
- 239000001856 Ethyl cellulose Substances 0.000 claims description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 4
- 229920001249 ethyl cellulose Polymers 0.000 claims description 4
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 4
- 229940113115 polyethylene glycol 200 Drugs 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 239000000080 wetting agent Substances 0.000 claims description 4
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 claims description 3
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 claims description 3
- 229940082484 carbomer-934 Drugs 0.000 claims description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 2
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 claims description 2
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 claims description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 2
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 claims description 2
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 229960004543 anhydrous citric acid Drugs 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 229960002303 citric acid monohydrate Drugs 0.000 claims description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 2
- 229960001031 glucose Drugs 0.000 claims description 2
- 229960003511 macrogol Drugs 0.000 claims description 2
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 2
- 239000004302 potassium sorbate Substances 0.000 claims description 2
- 235000010241 potassium sorbate Nutrition 0.000 claims description 2
- 229940069338 potassium sorbate Drugs 0.000 claims description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 239000001509 sodium citrate Substances 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- 229960001790 sodium citrate Drugs 0.000 claims description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 claims 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims 1
- 229960003415 propylparaben Drugs 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 23
- 210000002200 mouth mucosa Anatomy 0.000 abstract description 13
- 238000002360 preparation method Methods 0.000 abstract description 13
- 230000000306 recurrent effect Effects 0.000 abstract description 10
- 230000009471 action Effects 0.000 abstract description 5
- 206010028034 Mouth ulceration Diseases 0.000 abstract description 4
- 230000029663 wound healing Effects 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 2
- 239000007787 solid Substances 0.000 abstract description 2
- 235000000177 Indigofera tinctoria Nutrition 0.000 abstract 1
- 238000003912 environmental pollution Methods 0.000 abstract 1
- 229940097275 indigo Drugs 0.000 abstract 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000007704 transition Effects 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000003760 magnetic stirring Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 231100000397 ulcer Toxicity 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 239000008118 PEG 6000 Substances 0.000 description 4
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 2
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 239000001263 FEMA 3042 Substances 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000001741 anti-phlogistic effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 230000005548 health behavior Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 235000015523 tannic acid Nutrition 0.000 description 2
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 2
- 229940033123 tannic acid Drugs 0.000 description 2
- 229920002258 tannic acid Polymers 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical group OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029219 regulation of pH Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Insects & Arthropods (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of Chinese medicine compound thermosensitive hydrogel agent treating oral ulcer disease, form as follows according to the raw material of percentage by weight: substrate 17 35%, medical material and herbal extract 5 30%, surplus is solvent；Described medical material and herbal extract are made up of Indigo Naturalis extracting solution, Chinese nutgall and auxiliary medical material；Described auxiliary medical material is one or both combinations in Pseudobulbus Bletillae (Rhizoma Bletillae) extracting solution, Borneolum Syntheticum medical material.This Chinese medicine compound thermosensitive hydrogel agent is using four kinds of Chinese medicine Indigo Naturaliss, Galla Chinensis, Pseudobulbus Bletillae (Rhizoma Bletillae), Borneolum Syntheticums as the most square, make thermosensitive hydrogel agent, the semi-solid preparation i.e. undergone phase transition it is administered at medicine-feeding part with solution state, have and strengthen medicine and oral mucosa time of contact, lower and prominent release effect, discharge medicine slowly, increase and absorb and effect of prolongation action time, wound healing can be accelerated, effectively treat recurrent oral ulceration, technical maturity, it is easily achieved industrialized production, preparation process only uses water and ethanol as Extraction solvent, there is no environmental pollution.
Description
Technical field
The present invention relates to technical field of Chinese medicines, a kind of Chinese medicine compound thermosensitive hydrogel treating oral ulcer disease
Agent.
Background technology
Recurrent aphtha (Recurrent Aphthous Ulcers, RAU) is also known as recurrent aphtha mouth
Inflammation, recurrent oral ulceration, recurrent aphtha, be a kind of disease that in oral ulcer disease, sickness rate is the highest, be common, send out
Raw in the non-keratosis of oral mucosa, circular or the shallow table ulcer of ellipticalness, have causalgia, recurrence, from the features such as limit, sickness rate
It is about 20%, in some specific crowd, may be up to 66%.The pathogenic factor of recurrent aphtha may have with many factors
Close, but its basic cause of disease and pathogenesis are not yet completely clearly, so the most still without radical cure method.For the treatment of this disease,
Specific medicament can not use, and the medicine long-term efficacy used is the best, and oral ulcer is mainly alleviated in current treatment
The frequency that patient's local pain and reduction oral ulcer occur, the most effective cure method.Doctor trained in Western medicine with anti-inflammatory analgetic, prevent
Secondary infection, promotion healing are principle, and Chinese medicine treatment disease emphasis entirety is dialectical to be treated, and in treatment, relatively doctor trained in Western medicine has one
Determine advantage.
Oral ulcer disease, such as recurrent oral ulceration, show effect on oral mucosa more, and the treatment that the traditional Chinese medical science is now commonly used should
The form of Chinese drug of disease has powder, decoction, pill etc..Above dosage form owing to dosage is big, poor compliance or in-convenience in use, make
The reason such as short with the time, uncertain therapeutic efficacy is cut, can not be accepted by patients and like in clinical practice.Due to oral mucosa area about
200cm2, blood flow enriches, and relatively skin is more easy to be penetrated by medicine, and it absorbs essentially parenteral approach, can avoid the first of liver and cross effect
Answer and gastrointestinal destroys and degraded；Oral mucosa route of administration is simple, and this approach there is a possibility that dosage is the most accurate,
Play the effect of low dose of big effect；Oral mucosa is administered can carry out local directed complete set according to optical clearing situation, it is simple to urgent
Remove, and compared to other mucosal drug delivery approach, oral mucosa is administered and cannot be easily caused mucosa injury.Therefore select oral mucosa to give
Prescription formula, acts on oral mucosa with the dosage form of thermosensitive hydrogel and is possible not only to increase the action effect of medicine, it is also possible to bring ratio
Preferably medication is experienced.Select the temperature sensitive type in-situ gel with temperature-sensitive, be administered with solution state and i.e. send out at medicine-feeding part
The semi-solid preparation of raw phase transformation, has reinforcement medicine and oral mucosa time of contact, increases and absorb and extend the excellent of action time
Point.Comparing and other water-soluable gel substrate, the temperature that P407 forms gel is relatively low, and concentration is the highest, and gel viscosity is the highest,
Gelation temperature is the lowest, and adhesion power is the strongest, and therefore thermosensitive hydrogel is with poloxamer188 as substrate.Treat oral ulcer at present
The patent that gel preparations in terms of disease is relevant, has a kind of chitosan disclosed in the patent of Application No. CN201410108970.3
Iodine Mel thermosensitive hydrogel, glycyrrhizic acid, enoxolone or its salt disclosed in the patent of Application No. CN200810047995.1 or its
Derivative temperature sensing gel rubber.It is preferable that these preparations have curative effect in terms for the treatment of oral ulcer, but its curative effect still has bigger
Room for promotion, the thermosensitive hydrogel agent researching and developing the more excellent treatment oral ulcer disease of a kind of curative effect will have huge social valency
Value and market value.
Summary of the invention
It is an object of the invention to provide a kind of Chinese medicine compound thermosensitive hydrogel agent treating oral ulcer disease, pass through oral cavity
Mucosal drug delivery, continuingly acts on active component and reaches slow releasing function in certain time, patient is by smearing liquid gel in affected part
And reaching gelling under body temperature, medicinal substances extract directly acts on affected part by oral mucosa, adds connecing of medicine and affected part
The time of touching, thus effectively accelerate wound healing, treating oral ulcer, patient has only to needs when be applied at any time affected part
I.e. can reach therapeutic effect.Not only being administered orally and be free from side effects, safety coefficient is high, it is thus also avoided that by life-time service antibiotic and change
Learning the Oral health behaviours equilibrium condition that synthetic drug causes, model of action and preferable therapeutic effect by a kind of gentleness are given especially
The good treatment that patient brings is experienced.
For achieving the above object, the present invention provides following technical scheme:
A kind of Chinese medicine compound thermosensitive hydrogel agent treating oral ulcer disease, forms as follows according to the raw material of percentage by weight: base
Matter 17-35%, medical material and herbal extract 5-30%, surplus is solvent.
As the further scheme of the present invention: described medical material and herbal extract are by Indigo Naturalis extracting solution, Chinese nutgall
With auxiliary medical material composition.
As the present invention further scheme: described auxiliary medical material be the one in Pseudobulbus Bletillae (Rhizoma Bletillae) extracting solution, Borneolum Syntheticum medical material or
Two kinds of combinations.
As the present invention further scheme: in described medical material and herbal extract, Indigo Naturalis extracting solution, Galla Chinensis extract
The weight ratio of liquid, Pseudobulbus Bletillae (Rhizoma Bletillae) extracting solution and Borneolum Syntheticum medical material is (4-8): (4-8): (0-2.5): (0.5-2.5).
As the present invention further scheme: the extraction conditions of described Indigo Naturalis extracting solution is: Extracting temperature 50-90 DEG C,
Extraction solvent 60-100% ethanol, extraction time 1-4 time, solid-liquid ratio 1:(1-3), after concentration, extracting solution crude drug concentration is 0.5-2g/
ml；The extraction conditions of described Chinese nutgall can be: Extracting temperature 30-60 DEG C, and Extraction solvent is water or 30-60% ethanol, carries
Take number of times 1-4 time, solid-liquid ratio 1:(1-3), after concentration, extracting solution crude drug concentration is 0.5-2g/ml；Carrying of described Pseudobulbus Bletillae (Rhizoma Bletillae) extracting solution
The condition of taking is: Extracting temperature 50-90 DEG C, and Extraction solvent is water, extraction time 1-4 time, solid-liquid ratio 1:(1-3), extract after concentration
Liquid crude drug concentration is 0.5-1g/ml.
As the present invention further scheme: described substrate is made up of poloxamer substrate and adjuvant, poloxamer base
Matter weight percent content in the Chinese medicine compound thermosensitive hydrogel agent of described treatment oral ulcer disease is 17-32%, and adjuvant exists
Weight percent content in the Chinese medicine compound thermosensitive hydrogel agent of described treatment oral ulcer disease is 0-6%.
As the present invention further scheme: described adjuvant is binding agent, wetting agent, preservative, stabilizer, PH regulation
The mixture of one or more in agent and release regulator.
As the present invention further scheme: described poloxamer substrate is selected from husky selected from poloxamer188 or pool Lip river
Nurse 188.
As the present invention further scheme: described binding agent is selected from polyethylene glycol 200 (PEG200), Polyethylene Glycol
300(PEG300), PEG400 (PEG400), Macrogol 600 (PEG600), Polyethylene Glycol 2 000(PEG2000), poly-
Ethylene glycol 4 000(PEG4000), Polyethylene Glycol 6 000(PEG6000), Polyethylene Glycol 8 000(PEG8000), carbomer 934,
Acritamer 940, Carbopol 941, hydroxypropyl methyl cellulose (HMPC), hydroxypropyl cellulose (HPC), sodium carboxymethyl cellulose
(CMC-Na) mixture of one or more and in ethyl cellulose (EC)；Described wetting agent is selected from glycerol, propylene glycol and mountain
A kind of or several mixture in pears alcohol；Described preservative and stabilizer are selected from methyl hydroxybenzoate, ethyl hydroxybenzoate, Ni Bo
A kind of or several mixture in gold propyl ester, soluble metyl hydroxybenzoate and potassium sorbate；Described PH regulator is selected from bicarbonate
A kind of or several mixture in sodium, citric acid monohydrate, anhydrous citric acid and sodium citrate；Described release regulator is selected from
A kind of or several mixture in anhydrous glucose, glycerol, sodium chloride and D-mannital.
As the present invention further scheme: described solvent is purified water.
Compared with prior art, the invention has the beneficial effects as follows:
The present invention is to pick out two kinds in the multiple side of condemning according to traditional Chinese medicine therapy recurrence oral ulcer to have significant curative effect
Medical material Indigo Naturalis and Galla Chinensis are as monarch drug, and auxiliary is with Pseudobulbus Bletillae (Rhizoma Bletillae) and Borneolum Syntheticum medical material, to reaching wound healing, strengthen treatment effect
The effect of fruit.In addition, the gel-type vehicle with temperature sensitive effect is selected to coordinate herbal extract, the active substance in its preparation
By forming gelling at wound surface, thus can reach to strengthen medicine and oral mucosa time of contact, increase and absorb and prolongation effect
Effect of time, can accelerate wound healing, effectively treatment recurrent oral ulceration disease, technical maturity, it is easy to accomplish industrialization
Produce.
Accompanying drawing explanation
Fig. 1 is the In-vitro release curves schematic diagram that embodiment 1 treats the Chinese medicine compound thermosensitive hydrogel agent of oral ulcer disease.
Detailed description of the invention
Below in conjunction with detailed description of the invention, technical scheme is described in more detail.
Embodiment 1
A kind of Chinese medicine compound thermosensitive hydrogel agent treating oral ulcer disease, formula is following (every 10g gel).
Its preparation method is: measures required purified water and is placed in the ice-water bath on magnetic stirring apparatus, the most slowly adds
Enter the poloxamer188 of precise, PEG6000, after poloxamer188 granule is flooded profit, pours weighed pyrometric cone into
In shape bottle, it is placed in stored refrigerated in refrigerator, until being clarified, without agglomerate, finely dispersed solution.Add in solution
0.95ml herbal extract and 0.05g Borneolum Syntheticum medical material, and weigh gel net weight, adding purified water and supply weight (10g), stirring is all
Even.
The mensuration of gelation temperature: use rotor method, by responsive to temperature type gel sample 5 g of preparation in cillin bottle,
Thermometer is inserted in gel solution.Being placed on heatable magnetic stirring apparatus by cillin bottle, slowly heat up, heating rate is 1
℃·min-1, the temperature that magnetic stir bar stops operating completely is Tgel, parallel assay 3 times.
The 3rd method by Chinese Pharmacopoeia (2015 editions) drug release determination method measures the In-vitro release curves of thermosensitive hydrogel.?
At (37 ± 0.5) DEG C, with 500 mL purified water as release medium, slurry processes, mixing speed is 100 r min-1.In 2h often
15min samples 5ml, supplements the release medium of synthermal same volume simultaneously.Taking-up dissolution medium, with after 50% methanol constant volume, shakes up,
High effective liquid chromatography for measuring Indigo Naturalis Related Component and the concentration of gallic acid, calculate release.
The In-vitro release curves of thermosensitive hydrogel is shown in accompanying drawing 1.
Embodiment 2
A kind of Chinese medicine compound thermosensitive hydrogel agent treating oral ulcer disease, formula is following (every 10g gel).
Its preparation method is: measures required purified water and is placed in the ice-water bath on magnetic stirring apparatus, the most slowly adds
Enter the PLURONICS F87 of precise, PEG6000, HMPC, pour into weighed after PLURONICS F87 granule is flooded profit
In triangular pyramidal bottle, it is placed in stored refrigerated in refrigerator, until being clarified, without agglomerate, finely dispersed solution.Add in solution
Entering 0.9ml herbal extract and 0.1g Borneolum Syntheticum medical material, and weigh gel net weight, add purified water and supply weight (10g), stirring is all
Even.
Embodiment 3
A kind of Chinese medicine compound thermosensitive hydrogel agent treating oral ulcer disease, formula is following (every 10g gel).
Its preparation method is: measures required purified water and is placed in the ice-water bath on magnetic stirring apparatus, the most slowly adds
Enter the poloxamer188 of precise, PEG6000, carbomer 934 and glycerol, pour into after poloxamer granule is flooded profit
In weighed triangular pyramidal bottle, it is placed in stored refrigerated in refrigerator, until being clarified, without agglomerate, finely dispersed solution.To
Solution glue adds 0.9ml herbal extract and 0.1g Borneolum Syntheticum medical material, and weighs gel net weight, add purified water and supply weight
(10g), stir.
Embodiment 4
A kind of Chinese medicine compound thermosensitive hydrogel agent treating oral ulcer disease, formula is following (every 10g gel).
Its preparation method is: measures required purified water and is placed in the ice-water bath on magnetic stirring apparatus, the most slowly adds
Enter poloxamer 118, PEG8000, Acritamer 940 and the glycerol of precise, fall after poloxamer 118 granule is flooded profit
Enter in weighed triangular pyramidal bottle, be placed in stored refrigerated in refrigerator, until being clarified, without agglomerate, finely dispersed solution.
In solution glue, add 2.5ml herbal extract and 0.5g Borneolum Syntheticum medical material, and weigh gel net weight, add purified water and supply weight
(10g), stir.
Embodiment 5
A kind of Chinese medicine compound thermosensitive hydrogel agent treating oral ulcer disease, formula is following (every 10g gel).
Its preparation method is: measures required purified water and is placed in the ice-water bath on magnetic stirring apparatus, the most slowly adds
Enter poloxamer 118, PEG2000, methyl hydroxybenzoate and the propylene glycol of precise, when poloxamer 118 granule is flooded profit
After pour in weighed triangular pyramidal bottle, be placed in stored refrigerated in refrigerator, until being clarified, without agglomerate, finely dispersed
Solution.In solution glue, add 0.45ml herbal extract and 0.05g Borneolum Syntheticum medical material, and weigh gel net weight, add purified water and mend
Heavy sensation in the foot amount (10g), stirs.
The Chinese medicine compound thermosensitive hydrogel agent of described treatment oral ulcer disease includes Indigo Naturalis, Galla Chinensis, Pseudobulbus Bletillae (Rhizoma Bletillae) and Borneolum Syntheticum, side
Middle Indigo Naturalis is salty-cold, has the merit of heat-clearing and toxic substances removing, cooling blood for hemostasis.For maculae caused by violent heat pathogen, heat in blood tells nosebleed, chest pain hemoptysis, aphtha, Zha
The cheek.Galla Chinensis stops blooding, removing dampness sore.Two medicines are same with both making the fiery of upper inflammation to dissipate, arresting bleeding and healing up ulcer granulation promoting again.Pseudobulbus Bletillae (Rhizoma Bletillae) clearing away heat-damp and promoting diuresis,
It is strong that astringing to arrest bleeding, detumescence and promoting granulation, and Galla Chinensis share not only hemostasis power, and promotes the healing of ulcer.The pungent perfume (or spice) of Borneolum Syntheticum is walked to alter, and is slightly cold
Let out clearly, external clearing away heat to alleviate pain, detumescence and promoting granulation, for controlling the good medicine that pyretic toxicity swells and ache.Modern pharmacology research show Indigo Naturalis have antibacterial,
Antiinflammatory, analgesia etc. act on.Galla Chinensis is because having precipitation containing tannic acid to protein, after skin, mucosa, ulcer contact tannic acid,
Its tissue protein is i.e. solidified, and forms one layer of tunicle and in astriction, the most oppressed contraction of thin vessels simultaneously, blood coagulates
Tie and play effect of hemostasis.Pseudobulbus Bletillae (Rhizoma Bletillae) has the effects such as hemostatic and antibacterial.Borneolum Syntheticum also has the effect of antimicrobial antiphlogistic pain relieving.Indigo Naturalis in side
With Galla Chinensis as monarch drug, two medicines share not only heat-clearing and toxic substances removing but also arresting bleeding and healing up ulcer granulation promoting, are aided with Pseudobulbus Bletillae (Rhizoma Bletillae) and Borneolum Syntheticum antimicrobial antiphlogistic pain relieving,
Cure mechanism is harmonious with pathogenesis.The most all medicines share to be had anti-inflammatory and antalgic, resisting pathogenic microbes, improves microcirculation etc. and make
With, can promote that Blood of Patients with Recurrent Oral topical ulcers heals, ease the pain, reduce recurrence, improve general curative effect, finally change
Kind quality of life.By using compound of Chinese medicine oral ulcer, use the extracted rear extracting solution of Chinese crude drug for preparation, effect
In oral mucosa, being not only administered orally and be free from side effects, safety coefficient is high, it is thus also avoided that by life-time service antibiotic and chemosynthesis
Oral health behaviours that medicine causes balance, is brought to patient by the model of action of a kind of gentleness and preferable therapeutic effect especially
Good treatment is experienced.
Above the better embodiment of the present invention is explained in detail, but the present invention is not limited to above-mentioned embodiment party
Formula, in the ken that one skilled in the relevant art is possessed, it is also possible on the premise of without departing from present inventive concept
Various changes can be made.
Claims (10)
1. the Chinese medicine compound thermosensitive hydrogel agent treating oral ulcer disease, it is characterised in that former according to percentage by weight
Material composition is as follows: substrate 17-35%, medical material and herbal extract 5-30%, surplus is solvent.
The Chinese medicine compound thermosensitive hydrogel agent for the treatment of oral ulcer disease the most according to claim 1, it is characterised in that described
Medical material and herbal extract are made up of Indigo Naturalis extracting solution, Chinese nutgall and auxiliary medical material.
The Chinese medicine compound thermosensitive hydrogel agent for the treatment of oral ulcer disease the most according to claim 2, it is characterised in that described
Auxiliary medical material is one or both combinations in Pseudobulbus Bletillae (Rhizoma Bletillae) extracting solution, Borneolum Syntheticum medical material.
The Chinese medicine compound thermosensitive hydrogel agent for the treatment of oral ulcer disease the most according to claim 3, it is characterised in that described
In medical material and herbal extract, the weight ratio of Indigo Naturalis extracting solution, Chinese nutgall, Pseudobulbus Bletillae (Rhizoma Bletillae) extracting solution and Borneolum Syntheticum medical material is (4-
8): (4-8): (0-2.5): (0.5-2.5).
The Chinese medicine compound thermosensitive hydrogel agent for the treatment of oral ulcer disease the most according to claim 4, it is characterised in that described
The extraction conditions of Indigo Naturalis extracting solution is: Extracting temperature 50-90 DEG C, Extraction solvent 60-100% ethanol, extraction time 1-4 time, feed liquid
Than 1:(1-3), after concentration, extracting solution crude drug concentration is 0.5-2g/ml；The extraction conditions of described Chinese nutgall can be: extracts
Temperature 30-60 DEG C, Extraction solvent is water or 30-60% ethanol, extraction time 1-4 time, solid-liquid ratio 1:(1-3), extracting solution after concentration
Crude drug concentration is 0.5-2g/ml；The extraction conditions of described Pseudobulbus Bletillae (Rhizoma Bletillae) extracting solution is: Extracting temperature 50-90 DEG C, and Extraction solvent is water,
Extraction time 1-4 time, solid-liquid ratio 1:(1-3), after concentration, extracting solution crude drug concentration is 0.5-1g/ml.
6. according to the Chinese medicine compound thermosensitive hydrogel agent of the treatment oral ulcer disease described in claim 1 or 2 or 3 or 4 or 5, its
Being characterised by, described substrate is made up of poloxamer substrate and adjuvant, and poloxamer substrate is in described treatment oral ulcer disease
Chinese medicine compound thermosensitive hydrogel agent in weight percent content be 17-32%, adjuvant is in described treatment oral ulcer disease
Weight percent content in medicine compound temperature-sensitivgel gel is 0-6%.
The Chinese medicine compound thermosensitive hydrogel agent for the treatment of oral ulcer disease the most according to claim 6, it is characterised in that described
Adjuvant is the mixture of one or more in binding agent, wetting agent, preservative, stabilizer, PH regulator and release regulator.
The Chinese medicine compound thermosensitive hydrogel agent for the treatment of oral ulcer disease the most according to claim 7, it is characterised in that described
Poloxamer substrate is selected from selected from poloxamer188 or PLURONICS F87.
The Chinese medicine compound thermosensitive hydrogel agent for the treatment of oral ulcer disease the most according to claim 8, it is characterised in that described
Binding agent is selected from polyethylene glycol 200 (PEG200), Liquid Macrogol (PEG300), PEG400 (PEG400), poly-second two
Alcohol 600(PEG600), Polyethylene Glycol 2 000(PEG2000), Polyethylene Glycol 4 000(PEG4000), Polyethylene Glycol 6 000
(PEG6000), Polyethylene Glycol 8 000(PEG8000), carbomer 934, Acritamer 940, Carbopol 941, hydroxypropyl methyl fiber
One or many in element (HMPC), hydroxypropyl cellulose (HPC), sodium carboxymethyl cellulose (CMC-Na) and ethyl cellulose (EC)
The mixture planted；The described wetting agent a kind of or several mixture in glycerol, propylene glycol and sorbitol；Described anticorrosion
Agent and stabilizer one in methyl hydroxybenzoate, ethyl hydroxybenzoate, propylparaben, soluble metyl hydroxybenzoate and potassium sorbate
Or several mixture；Described PH regulator is in sodium bicarbonate, citric acid monohydrate, anhydrous citric acid and sodium citrate
Or several a kind of mixture；Described release regulator is in anhydrous glucose, glycerol, sodium chloride and D-mannital
Or several a kind of mixture.
The Chinese medicine compound thermosensitive hydrogel agent for the treatment of oral ulcer disease the most according to claim 9, it is characterised in that institute
Stating solvent is purified water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610716756.5A CN106138129A (en) | 2016-08-25 | 2016-08-25 | A kind of Chinese medicine compound thermosensitive hydrogel agent treating oral ulcer disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610716756.5A CN106138129A (en) | 2016-08-25 | 2016-08-25 | A kind of Chinese medicine compound thermosensitive hydrogel agent treating oral ulcer disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106138129A true CN106138129A (en) | 2016-11-23 |
Family
ID=57342587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610716756.5A Pending CN106138129A (en) | 2016-08-25 | 2016-08-25 | A kind of Chinese medicine compound thermosensitive hydrogel agent treating oral ulcer disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106138129A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107375193A (en) * | 2017-06-23 | 2017-11-24 | 江西医学高等专科学校 | A kind of Chinese medicine compound prescription rectally thermo-sensitive gel agent and preparation method thereof |
| CN108061766A (en) * | 2017-12-05 | 2018-05-22 | 江西中医药大学 | A kind of method of quality control of Fructus Hordei Germinatus granule |
| CN110267672A (en) * | 2016-12-20 | 2019-09-20 | 首尔大学医院 | It include the pharmaceutical composition of Indigo Naturalis extract or its fraction as effective component for prevent or treat inflammatory bowel disease |
| CN113057981A (en) * | 2021-03-12 | 2021-07-02 | 江苏苏赋科技发展有限公司 | Compound temperature-sensitive gel and preparation method and application thereof |
| CN114767622A (en) * | 2022-04-19 | 2022-07-22 | 四川省医学科学院·四川省人民医院 | Lycium barbarum glycopeptide hydrogel for preventing or treating oral ulcer and preparation method and application thereof |
| CN115025125A (en) * | 2022-06-24 | 2022-09-09 | 四川大学 | A pharmaceutical composition for treating oral ulcer and preparation method thereof |
| CN115844993A (en) * | 2022-12-13 | 2023-03-28 | 湖南倍青生物科技有限公司 | A Chinese medicinal disinfectant for oral cavity and skin, and its preparation method |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104138350A (en) * | 2013-05-06 | 2014-11-12 | 上海中医药大学 | Baicalein temperature-sensitive gel, preparing method thereof and applications of the gel |
-
2016
- 2016-08-25 CN CN201610716756.5A patent/CN106138129A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104138350A (en) * | 2013-05-06 | 2014-11-12 | 上海中医药大学 | Baicalein temperature-sensitive gel, preparing method thereof and applications of the gel |
Non-Patent Citations (2)
| Title |
|---|
| 张恩虎: "《实用临床中药手册》", 31 January 2001, 人民军医出版社 * |
| 王颖 等: "星点设计-效应面法优化黄榆温度敏感型凝胶处方", 《中国新药杂志》 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110267672A (en) * | 2016-12-20 | 2019-09-20 | 首尔大学医院 | It include the pharmaceutical composition of Indigo Naturalis extract or its fraction as effective component for prevent or treat inflammatory bowel disease |
| CN107375193A (en) * | 2017-06-23 | 2017-11-24 | 江西医学高等专科学校 | A kind of Chinese medicine compound prescription rectally thermo-sensitive gel agent and preparation method thereof |
| CN108061766A (en) * | 2017-12-05 | 2018-05-22 | 江西中医药大学 | A kind of method of quality control of Fructus Hordei Germinatus granule |
| CN113057981A (en) * | 2021-03-12 | 2021-07-02 | 江苏苏赋科技发展有限公司 | Compound temperature-sensitive gel and preparation method and application thereof |
| CN114767622A (en) * | 2022-04-19 | 2022-07-22 | 四川省医学科学院·四川省人民医院 | Lycium barbarum glycopeptide hydrogel for preventing or treating oral ulcer and preparation method and application thereof |
| CN114767622B (en) * | 2022-04-19 | 2023-06-09 | 四川省医学科学院·四川省人民医院 | Lycium barbarum glycopeptide hydrogel for preventing or treating dental ulcer and preparation method and application thereof |
| CN115025125A (en) * | 2022-06-24 | 2022-09-09 | 四川大学 | A pharmaceutical composition for treating oral ulcer and preparation method thereof |
| CN115025125B (en) * | 2022-06-24 | 2023-09-29 | 四川大学 | Pharmaceutical composition for treating dental ulcer and preparation method thereof |
| CN115844993A (en) * | 2022-12-13 | 2023-03-28 | 湖南倍青生物科技有限公司 | A Chinese medicinal disinfectant for oral cavity and skin, and its preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106138129A (en) | A kind of Chinese medicine compound thermosensitive hydrogel agent treating oral ulcer disease | |
| JP6375037B2 (en) | Pharmaceutical composition containing crude drugs (組成) | |
| CN105561289B (en) | It is a kind of for treating the pharmaceutical preparation of canker sore | |
| CN111358839B (en) | Formula granules of polygonum capitatum and preparation method thereof | |
| CN102120001B (en) | Jiuhua hemorrhoid suppository and preparation method thereof | |
| US11129863B2 (en) | Composition, preparation method thereof, and application thereof in the prevention and treatment of mammary gland disease | |
| CN105434840A (en) | Manufacturing method for Chuanshentong preparation | |
| CN109223706A (en) | A kind of progress in Intelligent Hydrogel and preparation method thereof for preventing and treating cervical disease | |
| CN103432518B (en) | A kind of externally-applied medicinal composition and preparation method thereof for the treatment of traumatic injury, arthromyodynia | |
| CN101940585B (en) | Composition with orientin-2' -O-beta-L-galactoside as main component and application thereof | |
| CN103599204B (en) | Chinese medicine composition and its preparation method and application | |
| CN102526387B (en) | Medicinal composition for treating early-stage diabetic foot and preparation method thereof | |
| CN102697703B (en) | Piroxicam gel preparation and preparation method thereof | |
| CN106176580A (en) | A kind of heat-sensitive gel containing matrine alkaloid and preparation method thereof | |
| CN113521290A (en) | Pharmaceutical composition, medicinal patch, and preparation method and application thereof | |
| CN109470788A (en) | A kind of method of quality control of FUKE QIANJIN PIAN | |
| CN101574504B (en) | Medical composition for treating mammary gland diseases and preparation method thereof | |
| CN109364148A (en) | A kind of FUKE QIANJIN PIAN and preparation method thereof | |
| Mulchenko et al. | On the issue of creating medicinal products based on the marsh cinquefoil | |
| CN105998232B (en) | Application of paliurus ramosissimus or extract thereof in preparation of medicine for treating acne | |
| CN114796176A (en) | A pharmaceutical composition for treating dermatoses, and its preparation method | |
| WO2024077488A1 (en) | Relinqing granules having improved biological activity and disease treatment method | |
| CN104000959A (en) | Traditional Chinese medicine composition for external use and application thereof | |
| CN102552678A (en) | Injectable red ginseng and dwarf lilyturf tuber temperature sensitive in-situ gel preparation and preparation method thereof | |
| CN108354998A (en) | A kind of extract and preparation method thereof for treating pelvic infecton |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161123 |
|
| RJ01 | Rejection of invention patent application after publication |